{"DataElement":{"publicId":"5629824","version":"1","preferredName":"Adjuvant Therapy Lapatinib Administered Agent End Date","preferredDefinition":"The date lapatinib therapy stopped","longName":"3812570v1.0:2179511v1.0","context":"NRG","contextVersion":"1","DataElementConcept":{"publicId":"3812570","version":"1","preferredName":"Adjuvant Therapy Lapatinib Administered","preferredDefinition":"Information related to the administration of lapatinib in an adjuvant setting.","longName":"ADJ_LAPATINIB","context":"Alliance","contextVersion":"1","ObjectClass":{"publicId":"2739022","version":"1","preferredName":"Adjuvant Therapy","preferredDefinition":"(AD-joo-vant) Treatment given after the primary treatment to increase the chances of a cure. Adjuvant therapy may include chemotherapy, radiation therapy, hormone therapy, or biological therapy.","longName":"C15675","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Adjuvant Therapy","conceptCode":"C15675","definition":"Any therapy that is administered to augment or stimulate other treatment modalities or to minimize or prevent disease recurrence subsequent to the main treatment plan.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4A116784-74A7-3C7F-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-04-04","endDate":null,"createdBy":"ALAIS","dateCreated":"2008-04-04","modifiedBy":"ONEDATA","dateModified":"2008-04-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2691677","version":"1","preferredName":"Lapatinib Administered","preferredDefinition":"The ditosylate salt of a synthetic, orally-active quinazoline with potential antineoplastic properties. Lapatinib reversibly blocks phosphorylation of the epidermal growth factor receptor (EGFR), ErbB2, and the Erk-1 and-2 and AKT kinases; it also inhibits cyclin D protein levels in human tumor cell lines and xenografts. EGFR and ErbB2 have been implicated in the growth of various tumor types.:Given.","longName":"C26653:C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lapatinib","conceptCode":"C26653","definition":"A synthetic, orally-active quinazoline with potential antineoplastic properties. Lapatinib reversibly blocks phosphorylation of the epidermal growth factor receptor (EGFR), ErbB2, and the Erk-1 and-2 and AKT kinases; it also inhibits cyclin D protein levels in human tumor cell lines and xenografts. EGFR and ErbB2 have been implicated in the growth of various tumor types.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3DA59B53-0598-01B9-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-29","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-10-29","modifiedBy":"ONEDATA","dateModified":"2007-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NCCTG CRF:North Central Cancer Treatment Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E1A80601-203D-6B0B-E040-BB89AD4306D3","latestVersionIndicator":"Yes","beginDate":"2013-07-16","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2013-07-16","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":" Changed from CTEP to Alliance for by script Fri Oct 25 15:25:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2179511","version":"1","preferredName":"Agent End Date","preferredDefinition":"The date when agent usage ended.","longName":"AGT_END_DT","context":"DCP","contextVersion":"1","type":"Non-enumerated","dataType":"DATE","minLength":"10","maxLength":"10","minValue":null,"maxValue":null,"decimalPlace":null,"format":"MM/DD/YYYY","PermissibleValues":[],"ConceptualDomain":{"publicId":"2008565","version":"1","preferredName":"Temporal concepts","preferredDefinition":"Time meaning: Like time, date, frequency, occurence,..etc","longName":"TEMPORAL_CONCEPTS","context":"SPOREs","contextVersion":"2.31","origin":null,"workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"B7822ECE-3F17-24F5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-02-25","endDate":null,"createdBy":"MEDVEDOH","dateCreated":"2003-02-25","modifiedBy":"SBREXT","dateModified":"2004-02-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2233081","version":"1","preferredName":"Date","preferredDefinition":"a particular day specified as the time something has, or will, happen.","longName":"C25164","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Date","conceptCode":"C25164","definition":"The particular day, month and year an event has happened or will happen.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F90B5E56-BB15-0F45-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-06-09","modifiedBy":"ONEDATA","dateModified":"2005-06-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CFCBA97B-CAC3-5D7B-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-12-31","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-12-31","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"End Date","type":"Preferred Question Text","description":"End Date","url":null,"context":"NRG"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4663CE25-39A3-3909-E053-F662850A6878","latestVersionIndicator":"Yes","beginDate":"2017-01-18","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-01-18","modifiedBy":"SARAHB","dateModified":"2017-10-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}